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RESULTS
METHODS
This material is the result of work supported with resources and
the use of facilities at the John D. Dingell VA Medical Center,
Detroit, MI.
-
Traumatic brain injury (TBI) is associated with chronic pain and persistent
neuroinflammation. Opioids are often prescribed in order to relieve pain
symptoms, but recent evidence suggests that their use negatively impacts the
neuropathology of TBI, contributing to exacerbation of behavioral
impairments and neuroinflammation. To understand the mechanisms that may
underlie these outcomes, the following signaling pathways were investigated
in the present work:
• The de-ubiquinating enzyme tumor necrosis factor a-induced protein
(TNFAIP)3 or A20, inhibits the inflammatory signaling transcription factor
nuclear factor (NF)-kB leading to attenuation of the inflammatory response
• A20-binding inhibitor of nuclear factor kB (ABIN-1), which physically
interacts with A20, also plays a role in the inhibition of NF-kB
Recent evidence demonstrated by Zhou, et al1 suggests that ABIN-1
negatively regulates µ-opioid receptors. Therefore, dysregulation of ABIN-1
may contribute to the neuropathology post-TBI, especially after treatment
with opioids.
Phase 1: Determine the protein expression of ABIN-1 in various brain
regions and the influence of neuroinflammation on ABIN-1
Previously, it was determined that ABIN-1 regulates the lipopolysaccharide-
(LPS) induced inflammatory response in chondrocytes2. Therefore, to
determine the role of neuroinflammation in ABIN-1 protein expression, 10-
week-old male mice were injected intraperitoneally with a single dose (10
mg/kg) of LPS or saline (control). Brain tissue and various peripheral tissues
were harvested and flash frozen 24 hours after LPS injection.
Phase 2: Determine the effect of TBI on ABIN-1 protein expression over
time
The effects of TBI on ABIN-1 protein expression will be investigated using
brain tissue from mice subjected to a moderate level TBI after 1, 7, and 10
days.
Phase 3: Determine the effect of morphine treatment post-TBI on
ABIN-1 protein expression
Zhou et al. demonstrated that ABIN-1 negatively regulates μ-opioid
receptors in an ABIN-1 overexpression model1. Considering this evidence,
morphine exposure post-TBI is likely to influence ABIN-1 expression.
Phase 3 will investigate this influence in brain tissue harvested from mice
treated with morphine after a moderate level TBI.




Antibodies: Cell Signaling – Anti-ABIN-1 polyclonal antibody #4664
Figure 1: Fluorescent immunoblot exhibiting a concentration gradient (µg) of ABIN-1 expression
at 80 kDa in prefrontal cortex (PFC) tissue harvested 24 hours after treatment with
lipopolysaccharide (LPS) or saline.
Figure 2: Enhanced chemiluminescence (ECL) immunoblot exhibiting a concentration gradient
(μg) of ABIN-1 expression at 80 kDa in the nucleus accumbens (NAc) harvested 24 hours after
treatment with lipopolysaccharide (LPS) or saline and splenic tissue harvested 2 hours after
treatment with LPS or saline.
Figure 3: Enhanced chemiluminescence (ECL) immunoblot exhibiting a concentration gradient
(μg) of ABIN-1 expression at 80 kDa in the prefrontal cortex (PFC) harvested 24 hours after
treatment with lipopolysaccharide (LPS) or saline and splenic tissue harvested 2 hours after
treatment with LPS or saline.
These results are preliminary. Work is still being completed
to investigate ABIN-1 protein expression in various brain
regions including the dorsal hippocampus, ventral
hippocampus, dorsal striatum, amygdala, anterior cingulate
cortex, and thalamus. Figure 1 & 2 demonstrate that LPS
may modulate ABIN-1 expression in the prefrontal cortex
(PFC) and the nucleus accumbens (NAc), 24 hours after
treatment with LPS.
Previous work suggests that ABIN-1 is highly expressed in
the splenic tissue3. Therefore, splenic tissue harvested from
mice 2 hours after treatment with a single dose of LPS was
used as a peripheral control of ABIN-1 protein expression.
Interestingly, Figure 2 & 3 may demonstrate a reduction in
splenic expression of ABIN-1, 2 hours after treatment with
LPS. This may be due to the downregulation of ABIN-1
protein expression after stimulation with LPS, which is
contradictory to the findings in other investigations2.
However, this may also be due to the mobilization of white
blood cells from the splenic tissue after activation by LPS.
If this is the case, we would expect ABIN-1 expression to
be reduced since there are less immune system modulating
cells present in the splenic tissue. Further work is being
completed in order to investigate this observation.
Since these findings are preliminary and the method is still
being optimized, it is difficult to make conclusions from
the presented data. However, further investigation may
elucidate the role of ABIN-1 in the central nervous system.
The findings of Zhou et al. have demonstrated a
relationship between inflammatory and μ-opioid receptor
signaling. As stated previously, TBI has been linked to
chronic pain. Opioids are often prescribed in order to
relieve symptoms. Since evidence suggests that opioids
may exacerbate neuroinflammation in the injured brain, the
role of the anti-inflammatory protein, ABIN-1, is of
particular interest.
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